Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

Trial Profile

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Paliperidone (Primary) ; Lithium
  • Indications Major depressive disorder; Suicidal ideation
  • Focus Therapeutic Use
  • Acronyms AFSP
  • Most Recent Events

    • 28 Jan 2016 No of arms changed from 2 to 3 with change in dose range of Paliperidone (3-6 mg/day to 1-5 mg/day) and addition of placebo arm as per ClinicalTrials.gov record.
    • 17 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top